Developing new small molecule treatments for myotonic dystrophy
Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy
This study is working on new medicines to help people with myotonic dystrophy by creating special compounds that can target and reduce the harmful RNA causing the condition, with the hope of easing symptoms and improving lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Albany NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project ID | NIH-11060026 on NIH RePORTER |
What this research studies
This research focuses on creating new small molecule therapeutics aimed at treating myotonic dystrophy, a neuromuscular disorder caused by toxic RNA. The approach involves designing modified polycyclic compounds that can selectively reduce the harmful expanded RNAs responsible for the disease. By understanding the mechanisms of action of these compounds, the research aims to identify effective drug candidates that can alleviate symptoms and improve patient outcomes. The study utilizes cell lines from patients with myotonic dystrophy to test the efficacy of these new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with myotonic dystrophy, particularly those with the DM1 or DM2 forms of the disease.
Not a fit: Patients with other forms of neuromuscular disorders unrelated to myotonic dystrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective new therapies that significantly improve the quality of life for patients with myotonic dystrophy.
How similar studies have performed: Previous research has shown promise with similar small molecule approaches in reducing toxic RNA levels in myotonic dystrophy, indicating potential for success in this novel therapeutic strategy.
Where this research is happening
Albany, United States
- State University of New York at Albany — Albany, United States (Active)
Researchers
- Principal investigator: Berglund, Andrew — State University of New York at Albany
- Study coordinator: Berglund, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.